KKALSHI
What will the FDA's decision be on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026?
Yes1%
Vol$0.00
Outcomes2
Markets
MarketKALSHIresolved
MarketKALSHIresolvedOther
What will the FDA's decision be on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026?
NoNo Price
100¢
|
VolTotal Volume
$0.00
|
Outcomes
2
Ends
Jan 8, 2027
in 3 monthsWhat will the FDA's decision be on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026?
No
100¢
|
Vol
$0.00
|
Outcomes
2
Yes0.5¢
No99.5¢
Price History
What will the FDA's decision be on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026?
No historical data available
Price history will appear here when available
Resolution Info
Market Stats
Last Updated
less than a minute ago